RPRX - Royalty Pharma • Dividends
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See below the complete and updated table with all dividends paid and declared history, etc
DY 1,6%
DY 1,6%
1/2
The latest dividend from RPRX was $0.235 per share (ex-dividend 8/14/2026). The dividend yield over the last 12 months is 1,6%. Over the last 12 months there were 4 distributions, totalling $0.925 per share.